Sitagliptin class
Pro Research Analysisby 
Searched over 200M research papers for "sitagliptin class"
Sitagliptin: A Comprehensive Overview of Its Class and Efficacy
Introduction to Sitagliptin and DPP-4 Inhibitors
Sitagliptin, marketed under names such as Januvia, Glactiv®, and Tesavel®, is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. DPP-4 inhibitors are a novel class of oral antihyperglycemic agents that enhance the body's ability to regulate blood glucose by increasing the active levels of incretins, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP)1 2 3.
Mechanism of Action
Sitagliptin works by inhibiting the DPP-4 enzyme, which is responsible for the rapid degradation of incretins. By inhibiting DPP-4, sitagliptin increases the levels of active GLP-1 and GIP, leading to enhanced insulin release and decreased glucagon secretion from pancreatic alpha-cells. This results in improved glycemic control2 3 10.
Clinical Efficacy
Monotherapy and Combination Therapy
Sitagliptin has been evaluated in various clinical settings, including as monotherapy and in combination with other antihyperglycemic agents. Clinical trials have shown that sitagliptin significantly reduces glycosylated hemoglobin (HbA1c) levels when used alone or in combination with metformin, pioglitazone, sulfonylureas, or insulin1 3 4. In monotherapy, sitagliptin was found to be noninferior to metformin in reducing HbA1c levels1. When used as an add-on therapy, sitagliptin was noninferior to glipizide and generally comparable to rosiglitazone1.
Hospital Management
In a multicenter, prospective, open-label, non-inferiority randomized trial, sitagliptin combined with basal insulin was found to be as effective and safe as the basal-bolus insulin regimen for managing hyperglycemia in hospitalized patients with type 2 diabetes. This suggests that sitagliptin can be a convenient alternative to more labor-intensive insulin regimens in hospital settings7.
Pharmacokinetics and Pharmacodynamics
Sitagliptin is orally bioavailable and undergoes minimal hepatic metabolism, with the majority being excreted unchanged in the urine. It dose-dependently inhibits plasma DPP-4 activity, leading to increased levels of active GLP-1 and GIP, which in turn enhance insulin secretion and reduce glucagon levels2 6 10. The pharmacokinetic profile supports once-daily dosing, making it a convenient option for patients6.
Safety and Tolerability
Sitagliptin is generally well tolerated, with a low risk of hypoglycemia and a neutral effect on body weight. Adverse effects are comparable to placebo, and significant hypoglycemia is rare unless combined with other agents that may cause hypoglycemia, such as sulfonylureas or insulin1 3 4. Concerns about pancreatic adverse events, such as pancreatitis, have not been substantiated by current evidence, and regulatory reviews have found little evidence to support these concerns8 9.
Conclusion
Sitagliptin, as a DPP-4 inhibitor, offers a valuable treatment option for patients with type 2 diabetes. Its efficacy in reducing HbA1c levels, favorable safety profile, and convenient oral administration make it a suitable choice for both monotherapy and combination therapy. While long-term studies are needed to further establish its safety, current evidence supports its use as an effective and well-tolerated antihyperglycemic agent.
Sources and full results
Most relevant research papers on this topic
Sitagliptin
Sitagliptin is a well-tolerated and effective treatment option for type 2 diabetes, with oral administration, a generally weight-neutral effect, and low risk of hypoglycemia.
RCT
Highly CitedEffect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Sitagliptin, a DPP-4 inhibitor, effectively lowers blood glucose levels in type 2 diabetes patients when it inhibits plasma DPP-4 activity by 80% and increases active GLP-1 and GIP levels by 2-fold or higher after an oral glucose tolerance test.
RCT
Very Rigorous JournalHighly CitedSitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials
Sitagliptin is an effective and well-tolerated oral DPP-4 inhibitor for glycemic control in patients with type 2 diabetes, offering potential as initial therapy or add-on therapy.
Systematic ReviewHighly CitedSitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.
Sitagliptin is an effective and well-tolerated oral DPP-4 inhibitor for glycemic control in patients with type 2 diabetes, and may be considered for initial therapy or add-on therapy.
Systematic ReviewHighly CitedPharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses
Sitagliptin shows promising pharmacokinetics and pharmacodynamics in healthy subjects, with potential for treating type 2 diabetes.
RCTHighly CitedPharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Multiple oral doses of sitagliptin show similar pharmacokinetic and pharmacodynamic properties and tolerability in healthy male volunteers with type 2 diabetes mellitus.
RCTHighly CitedEfficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial.
Sitagliptin-basal insulin is as effective as a basal-bolus insulin regimen for managing type 2 diabetes in hospitalized patients, with similar duration of stay and blood glucose control.
RCTHighly CitedSitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Sitagliptin is an effective and generally well-tolerated treatment option for patients with type 2 diabetes, improving glycemic control and reducing the risk of hypoglycemia.
Literature ReviewHighly CitedThe Biological Impacts of Sitagliptin on the Pancreas of a Rat Model of Type 2 Diabetes Mellitus: Drug Interactions with Metformin
Sitagliptin has a cytoprotective effect on beta-cell damage and does not show any detrimental effects on the exocrine pancreas in a rat model of type 2 diabetes mellitus.
RCT
Animal StudySitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Sitagliptin phosphate significantly reduces HbA(1c) levels in type 2 diabetes patients when used alone or in combination with metformin or pioglitazone, and is well-tolerated.
Systematic ReviewHighly Cited